Vijaya Diagnostic Centre board approved the acquisition of Arya Wellness Centre's diagnostic operations in Assam for ₹46.20 crore through a slump sale on September 11, 2026. The deal marks the company's strategic entry into the North-East India diagnostics market.

Acquisition details

The transaction involves the purchase of Arya Wellness Centre's diagnostic business in Assam as a going concern through a slump sale structure from NEMRIL HRPL JV (North Eastern Medical Research Institute Limited – Hexagon Research Private Limited JV). The deal is subject to customary closing working capital adjustments and requisite statutory approvals.

A slump sale involves the transfer of a business undertaking as a whole, including all its assets and liabilities, for a lump sum consideration without assigning individual values to each component. This structure is commonly used in corporate acquisitions of operational business units.

Target financials

The target entity operates within the Healthcare and Diagnostics industry, providing comprehensive pathology and radiology services on a B2C basis. The following table outlines the historical turnover of the acquired business:

In FY26, the business recorded revenue from operations of ~₹26 cr. with IND AS EBITDA of ₹5.6 cr. and IND AS Adjusted PAT of ₹2.5 cr. The business mix comprises 56% pathology and 44% radiology. Over 85% of revenues are generated from the B2C segment.

The proposed transaction does not constitute a related party transaction. The promoter, promoter group, and group companies of Vijaya Diagnostic Centre do not hold any interest in the seller entity.

Strategic context

The acquisition extends Vijaya Diagnostic Centre's presence into Assam, adding an established diagnostic network in the northeastern region to its portfolio. The deal was sanctioned at the board level, underscoring the company's commitment to geographic expansion through inorganic growth. The transaction is tentatively expected to be completed within 90 days, or such extended period as may be mutually agreed upon by the parties, subject to the fulfilment of customary conditions precedent specified in the Business Transfer Agreement.

What the Numbers Show

The acquisition price of ₹46.20 crore implies a valuation multiple of approximately 8.2x on the target's FY26 IND AS EBITDA of ₹5.6 crore. This aligns with management's stated valuation range of ~8–9x EBITDA. With an adjusted PAT of ₹2.5 crore, the transaction is expected to be EPS accretive from the outset.

Vijaya Diagnostic Centre will host an institutional investor meeting on September 10, 2026. The event, organized by Emkay Global, aims to facilitate discussions with analysts and investors regarding the company's operations and outlook.

The meeting is scheduled for Thursday, September 10, 2026, starting at 11:00 am IST. It will take place at the company's office in JP Nagar, Bengaluru. The format includes both group and one-on-one sessions conducted in person.

Meeting Details

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Narasimha Raju K A, Chief Financial Officer, signed the intimation letter dated September 2, 2026.

Key Notes

• Discussions will be based strictly on publicly available information. No unpublished price-sensitive information will be shared during the meetings.
• The schedule is subject to change due to exigencies on the part of participants or the company.
• Investors and analysts may approach the company subsequently for clarifications regarding the discussions held during the meeting.